Seroatlas · Human Serome Atlas

TRIP4

Activating signal cointegrator 1

Also known as: ASC-1, HsT17391, TRIP4_HUMAN, ZC2HC5

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q15650
Gene: TRIP4
Ensembl: ENSG00000103671
Chromosome: 15
Canonical length: 581 aa
Protein class: Cancer-related genes, Disease related genes, Human disease related genes, Predicted intracellular proteins
Subcellular location: Nucleoplasm,Nuclear bodies

OverviewNCBI Gene

This gene encodes a subunit of the tetrameric nuclear activating signal cointegrator 1 (ASC-1) complex, which associates with transcriptional coactivators, nuclear receptors and basal transcription factors to facilitate nuclear receptors-mediated transcription. This protein is localized in the nucleus and contains an E1A-type zinc finger domain, which mediates interaction with transcriptional coactivators and ligand-bound nuclear receptors, such as thyroid hormone receptor and retinoid X receptor alpha, but not glucocorticoid receptor. Mutations in this gene are associated with spinal muscular atrophy with congenital bone fractures-1 (SMABF1). [provided by RefSeq, Apr 2016]

Canonical amino-acid sequenceUniProt

581 residues, UniProt reviewed canonical sequence.

>Q15650|TRIP4
     1  MAVAGAVSGE PLVHWCTQQL RKTFGLDVSE EIIQYVLSIE SAEEIREYVT DLLQGNEGKK
    61  GQFIEELITK WQKNDQELIS DPLQQCFKKD EILDGQKSGD HLKRGRKKGR NRQEVPAFTE
   121  PDTTAEVKTP FDLAKAQENS NSVKKKTKFV NLYTREGQDR LAVLLPGRHP CDCLGQKHKL
   181  INNCLICGRI VCEQEGSGPC LFCGTLVCTH EEQDILQRDS NKSQKLLKKL MSGVENSGKV
   241  DISTKDLLPH QELRIKSGLE KAIKHKDKLL EFDRTSIRRT QVIDDESDYF ASDSNQWLSK
   301  LERETLQKRE EELRELRHAS RLSKKVTIDF AGRKILEEEN SLAEYHSRLD ETIQAIANGT
   361  LNQPLTKLDR SSEEPLGVLV NPNMYQSPPQ WVDHTGAASQ KKAFRSSGFG LEFNSFQHQL
   421  RIQDQEFQEG FDGGWCLSVH QPWASLLVRG IKRVEGRSWY TPHRGRLWIA ATAKKPSPQE
   481  VSELQATYRL LRGKDVEFPN DYPSGCLLGC VDLIDCLSQK QFKEQFPDIS QESDSPFVFI
   541  CKNPQEMVVK FPIKGNPKIW KLDSKIHQGA KKGLMKQNKA V

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against TRIP4 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Intracellular
Secreted: No
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.46
Highest tissue expression: 26 nTPM

Expression across tissuesHPA

Tissue

kidney: 26 nTPM
thyroid gland: 24 nTPM
esophagus: 19 nTPM
parathyroid gland: 19 nTPM
thymus: 19 nTPM
rectum: 18 nTPM

Single-cell type

proximal tubule cells: 95 nCPM
neutrophils: 72 nCPM
neutrophil progenitors: 72 nCPM
esophageal apical cells: 65 nCPM
fibro-adipogenic progenitors: 65 nCPM
endometrial ciliated cells: 61 nCPM

Immune cell

basophil: 70 nTPM
eosinophil: 54 nTPM
non-classical monocyte: 43 nTPM
neutrophil: 31 nTPM
intermediate monocyte: 29 nTPM
T-reg: 23 nTPM

Brain region

white matter: 13 nTPM
choroid plexus: 12 nTPM
medulla oblongata: 11 nTPM
thalamus: 11 nTPM
basal ganglia: 11 nTPM
pons: 10 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about TRIP4.

Disease | AllUniProt

Conditions TRIP4 is implicated in, by any mechanism.

Spinal muscular atrophy with congenital bone fractures 1 (SMABF1) MIM:616866
Muscular dystrophy, congenital, Davignon-Chauveau type (MDCDC) MIM:617066

Disease | GeneticClinVar

32 pathogenic / likely-pathogenic of 349 ClinVar records.

Conditions with pathogenic or likely-pathogenic variants.

Spinal muscular atrophy with congenital bone fractures 1
TRIP4-related disorder
Congenital muscular dystrophy-respiratory failure-skin abnormalities-joint hyperlaxity syndrome
Centronuclear myopathy
Gastric cancer

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 0.67
gnomAD pLI: 0
gnomAD missense Z: 0.57
DepMap mean gene effect: -0.17
DepMap dependency class: selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 5% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

ASCH domain
PUA-like superfamily
TRIP4/RQT4, C2HC5-type zinc finger
Activating signal cointegrator 1-like
Activating signal cointegrator 1, third domain
Activating signal cointegrator 1, N-terminal
ASCH domain
Putative zinc finger motif, C2HC5-type
TRIP4, third domain
TRI4 N-terminal domain

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of TRIP4 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads TRIP4 as an antibody target. Whether an autoantibody or antibody against TRIP4 could matter depends on whether native TRIP4 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

TRIP4 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label TRIP4 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...